Skip to content
OpenCapital
Get started

Seaport Therapeutics SPTX Cumulative Translation Adjustment

Other financials

Income statement

See full
Operating income-$27.5M-70.2%
Net income-$25.4M-93.6%
EPS (diluted)-$10.34-83.0%

Balance sheet

See full
Cash & equivalents$52.9M—
Total debt$5.3M—
Total equity-$115.6M-220%
Total assets$227.7M—

Cash flow

See full
Operating cash flow-$20.2M+0.2%
CapEx--100%
Free cash flow-$20.2M+0.4%

Valuation

See full
Market cap$972.65M—
Enterprise value$925.08M—

Returns & leverage

See full
Debt / equity-0×—
Current ratio13.2×—

Where this comes from

Reported directly by Seaport Therapeutics in its filing.

Tagged under the XBRL concept sptx:CumulativeTranslationAdjustment.

The official record: Seaport Therapeutics ’s 10-Q, filed June 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Seaport Therapeutics 's cumulative translation adjustment.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Seaport Therapeutics 's cumulative translation adjustment?
Seaport Therapeutics (SPTX) reported cumulative translation adjustment of $0 in Q1 2026.